ARCH Venture Partners IX, LLC

SEC Form 4 insider trading activity

ARCH Venture Partners IX, LLC has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 5, 2026.

On the most recent filing, ARCH Venture Partners IX, LLC is listed as 10% Owner at Lyell Immunopharma, Inc. Inside the rolling window, ARCH Venture Partners IX, LLC reported 2 open-market purchases totaling $37.5M in LYEL and no open-market sales. The largest disclosed transaction in the window is a purchase of 2,321,262 LYEL shares on Nov 4, 2026, worth $25.0M.

Companies traded

Other insiders at LYEL

Insider Buying

$37.5M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LYEL
ARCH Venture Partners IX, LLC
Purchase$25.0MNov 5SEC ↗
LYEL
ARCH Venture Partners IX, LLC
Purchase$12.5MMar 9SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has ARCH Venture Partners IX, LLC made?

ARCH Venture Partners IX, LLC has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does ARCH Venture Partners IX, LLC trade?

ARCH Venture Partners IX, LLC has filed SEC Form 4 disclosures for 1 company, including LYEL.

When was ARCH Venture Partners IX, LLC's most recent SEC Form 4 filing?

ARCH Venture Partners IX, LLC's most recent SEC Form 4 filing on Tracefour is dated Nov 5, 2026.

What is ARCH Venture Partners IX, LLC's total buy and sell value in the current window?

Inside the rolling retention window, ARCH Venture Partners IX, LLC bought $37.5M and sold $0 based on SEC Form 4 filings.

What was ARCH Venture Partners IX, LLC's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 2,321,262 LYEL shares on 2026-11-04, worth $25.0M, per SEC Form 4 filings.